Literature DB >> 9859939

Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment.

M O Leach1, M Verrill, J Glaholm, T A Smith, D J Collins, G S Payne, J C Sharp, S M Ronen, V R McCready, T J Powles, I E Smith.   

Abstract

A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2-4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri-phosphate (TNTP) (p = 0.02) over 3 (+/-1) weeks were significantly associated with response, as were the levels of PME (p<0.001), PDE (p = 0.01), TP (p = 0.001) and TNTP (p = 0.007) at week 3 (+/-1). PME at week 3 (+/-1) was also significantly associated with the best volume response to treatment (p = 0.03). A reproducibility analysis of results from the observation of normal breast metabolism in four volunteers showed a mean coefficient of variation of 25%, after correcting for changes resulting from the menstrual cycle. Reproducibility studies in four patients with breast cancer showed a mean coefficient of variation of 33%, with the reproducibility being better in patients measured on different days (difference in TP was -6%) compared with those measured on the same day (difference in TP was -29%).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9859939     DOI: 10.1002/(sici)1099-1492(1998110)11:7<314::aid-nbm522>3.0.co;2-z

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  33 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models.

Authors:  Erika R Amstalden van Hove; Tiffany R Blackwell; Ivo Klinkert; Gert B Eijkel; Ron M A Heeren; Kristine Glunde
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 3.  Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases.

Authors:  Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-09-15       Impact factor: 4.044

4.  Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.

Authors:  Christopher S Ward; Humsa S Venkatesh; Myriam M Chaumeil; Alissa H Brandes; Mark Vancriekinge; Hagit Dafni; Subramaniam Sukumar; Sarah J Nelson; Daniel B Vigneron; John Kurhanewicz; C David James; Daphne A Haas-Kogan; Sabrina M Ronen
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

5.  Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods.

Authors:  Barjor Gimi; Arvind P Pathak; Ellen Ackerstaff; Kristine Glunde; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2005-04-01       Impact factor: 10.961

Review 6.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12

7.  Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors.

Authors:  J M Park; J H Park
Journal:  Korean J Radiol       Date:  2001 Apr-Jun       Impact factor: 3.500

8.  Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.

Authors:  Mounia Beloueche-Babari; Vaitha Arunan; L Elizabeth Jackson; Nina Perusinghe; Swee Y Sharp; Paul Workman; Martin O Leach
Journal:  Oncotarget       Date:  2010-07

9.  Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.

Authors:  Mark G Swanson; Kayvan R Keshari; Z Laura Tabatabai; Jeffry P Simko; Katsuto Shinohara; Peter R Carroll; Andrew S Zektzer; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2008-07       Impact factor: 4.668

Review 10.  Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.

Authors:  M Beloueche-Babari; Y-L Chung; N M S Al-Saffar; M Falck-Miniotis; M O Leach
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.